Company Sees FY26 Adjusted EBITDA Loss of $20M to Flat
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy NVCR?
Sees FY26 adjusted EBITDA loss of $20M to flat. The company said, "This guidance assumes full-year low-to-mid single digit net revenue growth from Optune Gio, net revenue contribution from Optune Lua and Optune Pax, collectively, between $15 million to $25 million, mid-70's percent gross margin, and foreign exchange rates as of December 31, 2025."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVCR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVCR
Wall Street analysts forecast NVCR stock price to rise
6 Analyst Rating
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 13.750
Low
13.50
Averages
23.58
High
39.00
Current: 13.750
Low
13.50
Averages
23.58
High
39.00
About NVCR
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NovoCure Reports Record Revenue and Growth in 2025 Earnings Call
- Significant Revenue Growth: NovoCure achieved a record net revenue of $655 million in 2025, reflecting an 8% year-over-year increase, particularly driven by active patient growth of 10% in Germany, 19% in France, and 29% in Japan.
- FDA Approval of New Therapy: The company announced that the first milestone for 2026 is the FDA approval of Optune Pax for locally advanced pancreatic cancer, which is expected to be a significant contributor to long-term growth, with regulatory filings also submitted in Europe and Japan.
- Management Changes: Chief Medical Officer Dr. Nicolas Leupin resigned effective February 25, with Dr. Uri Weinberg taking over the role, indicating that management stability and expertise will be crucial for future product launches and market strategies.
- 2026 Outlook: The company projects net revenue guidance of $675 million to $705 million for 2026, with an adjusted EBITDA target of breakeven, demonstrating confidence in new market launches and operational efficiency.
See More
Novocure to Participate in Global Healthcare Conference
- Management Participation: Novocure's CEO Frank Leonard and CFO Christoph Brackmann will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026, showcasing the company's latest advancements in oncology treatment.
- Investor Engagement: Throughout the event, management will also hold one-on-one meetings with investors, aiming to strengthen relationships with potential investors and enhance the company's visibility in the capital markets.
- Live Streaming and Replay: The live audio of the presentation will be accessible via Novocure's Investor Relations page, with a replay available for at least 14 days post-event, ensuring that investors who cannot attend live can still access the information.
- Company Overview: Novocure is a global oncology company focused on extending survival for patients with aggressive cancers through its innovative therapy, Tumor Treating Fields, which is approved in various countries for multiple cancer types.
See More
Novocure to Participate in Global Healthcare Conference
- Management Participation: Novocure's CEO Frank Leonard and CFO Christoph Brackmann will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026, showcasing the company's latest advancements in cancer treatment, which is expected to attract investor interest.
- Investor Interaction Opportunities: Throughout the event, management will also hold one-on-one meetings with investors, which not only helps to bolster investor confidence but may also promote stability and growth in the company's stock price.
- Innovative Treatment Solutions: Novocure focuses on extending patient survival through its Tumor Treating Fields technology, which has been approved in several countries for treating various cancers, demonstrating its potential in the global oncology market.
- Global Business Layout: With its headquarters in Baar, Switzerland, and R&D facilities in New Hampshire and Israel, the company indicates a strategic global presence aimed at driving business growth through ongoing research and development efforts.
See More
NovoCure Q4 Earnings Beat Expectations with Positive Guidance
- Earnings Highlights: NovoCure reported a Q4 GAAP EPS of -$0.22, beating expectations by $0.19, indicating a positive trend in profitability improvement, while revenue reached $174.35 million, an 8.1% year-over-year increase, surpassing market expectations by $0.99 million, reflecting sustained demand for its products.
- 2026 Financial Guidance: The company’s guidance for 2026 indicates total net revenues expected between $675 million and $705 million, with adjusted EBITDA projected at -$20 million to $0, suggesting a gradual improvement in growth potential and profitability over the coming years.
- FDA Approval Impact: NovoCure's recent FDA approval for Optune Pax for pancreatic cancer is anticipated to provide a new revenue stream and further solidify its market position in oncology, driving future performance growth.
- Positive Market Reaction: Following the earnings release, NovoCure's shares surged, reflecting investor optimism regarding the company's growth prospects, particularly in light of new product launches and market expansion, which bolstered market confidence.
See More
NovoCure Q4 Earnings Announcement Scheduled
- Earnings Release Date: NovoCure is set to announce its Q4 earnings on February 26 before market open, with a consensus EPS estimate of -$0.41, reflecting a 32.8% year-over-year improvement, indicating potential recovery in profitability.
- Revenue Expectations: The anticipated revenue for Q4 is $173.36 million, representing a 7.5% year-over-year increase, which suggests stable market demand and could bolster investor confidence in the company's growth trajectory.
- Historical Performance: Over the past year, NovoCure has beaten EPS estimates 75% of the time and revenue estimates 75% of the time, demonstrating consistency in financial performance that may attract more investor interest.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 4 downward revisions, while revenue estimates experienced 5 upward revisions and 1 downward revision, reflecting mixed market sentiment regarding the company's future performance.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Cancer Treatment
- Surge in Clinical Trials: Over 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA, based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than existing therapies, suggesting a faster approval timeline.
- Significant Survival Extension: In clinical trials, patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, highlighting the drug's potential market value of up to $5 billion in a challenging cancer segment.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, reflecting the company's commitment to expanding its clinical development efforts and enhancing operational capabilities.
See More
NovoCure Reports Record Revenue and Growth in 2025 Earnings Call
- Significant Revenue Growth: NovoCure achieved a record net revenue of $655 million in 2025, reflecting an 8% year-over-year increase, particularly driven by active patient growth of 10% in Germany, 19% in France, and 29% in Japan.
- FDA Approval of New Therapy: The company announced that the first milestone for 2026 is the FDA approval of Optune Pax for locally advanced pancreatic cancer, which is expected to be a significant contributor to long-term growth, with regulatory filings also submitted in Europe and Japan.
- Management Changes: Chief Medical Officer Dr. Nicolas Leupin resigned effective February 25, with Dr. Uri Weinberg taking over the role, indicating that management stability and expertise will be crucial for future product launches and market strategies.
- 2026 Outlook: The company projects net revenue guidance of $675 million to $705 million for 2026, with an adjusted EBITDA target of breakeven, demonstrating confidence in new market launches and operational efficiency.
See More
Novocure to Participate in Global Healthcare Conference
- Management Participation: Novocure's CEO Frank Leonard and CFO Christoph Brackmann will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026, showcasing the company's latest advancements in oncology treatment.
- Investor Engagement: Throughout the event, management will also hold one-on-one meetings with investors, aiming to strengthen relationships with potential investors and enhance the company's visibility in the capital markets.
- Live Streaming and Replay: The live audio of the presentation will be accessible via Novocure's Investor Relations page, with a replay available for at least 14 days post-event, ensuring that investors who cannot attend live can still access the information.
- Company Overview: Novocure is a global oncology company focused on extending survival for patients with aggressive cancers through its innovative therapy, Tumor Treating Fields, which is approved in various countries for multiple cancer types.
See More
Novocure to Participate in Global Healthcare Conference
- Management Participation: Novocure's CEO Frank Leonard and CFO Christoph Brackmann will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026, showcasing the company's latest advancements in cancer treatment, which is expected to attract investor interest.
- Investor Interaction Opportunities: Throughout the event, management will also hold one-on-one meetings with investors, which not only helps to bolster investor confidence but may also promote stability and growth in the company's stock price.
- Innovative Treatment Solutions: Novocure focuses on extending patient survival through its Tumor Treating Fields technology, which has been approved in several countries for treating various cancers, demonstrating its potential in the global oncology market.
- Global Business Layout: With its headquarters in Baar, Switzerland, and R&D facilities in New Hampshire and Israel, the company indicates a strategic global presence aimed at driving business growth through ongoing research and development efforts.
See More
NovoCure Q4 Earnings Beat Expectations with Positive Guidance
- Earnings Highlights: NovoCure reported a Q4 GAAP EPS of -$0.22, beating expectations by $0.19, indicating a positive trend in profitability improvement, while revenue reached $174.35 million, an 8.1% year-over-year increase, surpassing market expectations by $0.99 million, reflecting sustained demand for its products.
- 2026 Financial Guidance: The company’s guidance for 2026 indicates total net revenues expected between $675 million and $705 million, with adjusted EBITDA projected at -$20 million to $0, suggesting a gradual improvement in growth potential and profitability over the coming years.
- FDA Approval Impact: NovoCure's recent FDA approval for Optune Pax for pancreatic cancer is anticipated to provide a new revenue stream and further solidify its market position in oncology, driving future performance growth.
- Positive Market Reaction: Following the earnings release, NovoCure's shares surged, reflecting investor optimism regarding the company's growth prospects, particularly in light of new product launches and market expansion, which bolstered market confidence.
See More
NovoCure Q4 Earnings Announcement Scheduled
- Earnings Release Date: NovoCure is set to announce its Q4 earnings on February 26 before market open, with a consensus EPS estimate of -$0.41, reflecting a 32.8% year-over-year improvement, indicating potential recovery in profitability.
- Revenue Expectations: The anticipated revenue for Q4 is $173.36 million, representing a 7.5% year-over-year increase, which suggests stable market demand and could bolster investor confidence in the company's growth trajectory.
- Historical Performance: Over the past year, NovoCure has beaten EPS estimates 75% of the time and revenue estimates 75% of the time, demonstrating consistency in financial performance that may attract more investor interest.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 4 downward revisions, while revenue estimates experienced 5 upward revisions and 1 downward revision, reflecting mixed market sentiment regarding the company's future performance.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Cancer Treatment
- Surge in Clinical Trials: Over 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA, based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than existing therapies, suggesting a faster approval timeline.
- Significant Survival Extension: In clinical trials, patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, highlighting the drug's potential market value of up to $5 billion in a challenging cancer segment.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, reflecting the company's commitment to expanding its clinical development efforts and enhancing operational capabilities.
See More
